Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Christian Buske(University Hospital Ulm), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Edvard Zhavrid, Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Jin Seok Kim(University of Ulsan), Aliaksandr Prokharau(9th City Clinical Hospital), Wojciech Jurczak(Jagiellonian University), Keumyoung Ahn(Celltrion (South Korea)), Won-Seog Kim(Samsung Medical Center), SangJoon Lee(Celltrion (South Korea)), SungHyun Kim(Celltrion (South Korea)), Mariana Vasilică(Institutul Clinic Fundeni), Rajnish Nagarkar(HCG Cancer Centre)
Cited by 9
Related Papers
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|604
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568